Match!
Niels Vande Casteele
University of California
InfliximabInflammatory bowel diseaseUlcerative colitisDiabetes mellitusMedicine
137Publications
24H-index
2,241Citations
What is this?
Publications 149
Newest
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
#2Robert Battat (UCSD: University of California, San Diego)H-Index: 11
Last. Larry J. Prokop (Mayo Clinic)H-Index: 35
view all 16 authors...
INTRODUCTION: We applied the Grading of Recommendations, Assessment, Development, and Evaluation framework to evaluate the performance of fecal calprotectin (FC) as an alternative to endoscopy in patients with moderate-to-severe ulcerative colitis (UC) treated with a biologic agent or tofacitinib. METHODS: Individual participant data from the trials of infliximab, golimumab, vedolizumab, and tofacitinib for UC were pooled to generate prevalence of endoscopic activity (Mayo endoscopy score) acros...
Source
#1Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
#2Vipul Jairath (UWO: University of Western Ontario)H-Index: 14
Last. WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
view all 8 authors...
Abstract Background & Aims Infliximab is effective treatment for moderate to severe ulcerative colitis (UC). Little is known about patient-related factors that might be used to predict endoscopic healing with infliximab therapy. Methods We analyzed data from 484 patients included in the randomized trials of the effects of infliximab therapy for patients with UC (ACT-1 and -2 UC trials). We used a 2-compartment population pharmacokinetic model to calculate baseline infliximab clearance. Two multi...
Source
#1Robert Battat (UCSD: University of California, San Diego)
#2Amy Hemperly (UCSD: University of California, San Diego)H-Index: 2
Last. Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
view all 11 authors...
Abstract Background & Aims Hospitalized patients with acute severe ulcerative colitis (ASUC) often require surgery. Although the tumor necrosis factor antagonist infliximab is an effective salvage therapy to prevent colectomy in patients with ASUC, optimal dosing is unclear. Calculated infliximab clearance has been associated important outcomes in patients with ulcerative colitis, but its utility in patients with ASUC has not been established. We assessed the relationship between calculated base...
Source
#1Edward Yang (UCSD: University of California, San Diego)H-Index: 6
#2Nicola R Panaccione (UWO: University of Western Ontario)H-Index: 1
Last. Remo Panaccione (U of C: University of Calgary)H-Index: 62
view all 11 authors...
BACKGROUND: Biologic therapies in patients with Crohn's disease often yield low clinical and endoscopic remission rates. After multiple failed therapies, combining two biologic therapies is possibly the sole medical alternative to recurrent surgery. However, data on this approach are limited. AIMS: To assess the efficacy and safety of concomitant use of two biologic therapies in the largest cohort to date of refractory Crohn's disease patients. METHODS: Data were extracted from Crohn's disease p...
Source
#1Azucena SalasH-Index: 33
#2Cristian Hernandez-Rocha (Mount Sinai Hospital)
Last. Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
view all 8 authors...
Cytokines are involved in intestinal homeostasis and pathological processes associated with inflammatory bowel disease (IBD). The biological effects of cytokines, including several involved in the pathology of Crohn’s disease and ulcerative colitis, occur as a result of receptor-mediated signalling through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) DNA-binding families of proteins. Although therapies targeting cytokines have revolutionized IBD therapy, the...
Source
#2Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
Inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are chronic inflammatory disorders of the gastrointestinal tract which are characterised, in part, by an imbalance in the production of several pro- and anti-inflammatory cytokines. Although various agents are effective for inducing and maintaining remission, approximately 20% of patients are treatment-refractory and require surgery. Parenterally administered monoclonal antibody-based biologics are associated with adve...
Source
#1Konstantinos Papamichael (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 18
#2W. Thomas Clarke (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 18
Last. Adam S. Cheifetz (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 34
view all 9 authors...
Source
#1Stéphane Paul (Jean Monnet University)H-Index: 26
#2Hubert Marotte (University of Lyon)H-Index: 22
Last. Niels Vande Casteele (UCSD: University of California, San Diego)H-Index: 24
view all 9 authors...
Anti-tumour necrosis factor (TNF) drugs are often prescribed for the treatment of rheumatoid arthritis (RA) and other immune-mediated inflammatory diseases. While this treatment has been shown to be effective in many patients, up to 40% of patients do not achieve disease control. Drug concentration in plasma may be a factor affecting the observed variability in therapeutic response. This study aimed to identify the plasma concentrations of the anti-TNF certolizumab pegol (CZP) associated with im...
Source
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
#2Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
Last. A Weiss (Montefiore Medical Center)H-Index: 4
view all 40 authors...
Abstract Background & Aims We created and validated a clinical decision support tool (CDST) to predict outcomes of vedolizumab therapy for ulcerative colitis (UC). Methods We performed logistic regression analyses of data from the GEMINI 1 trial, from 620 patients with UC who received vedolizumab induction and maintenance therapy (derivation cohort), to identify factors associated with corticosteroid-free remission (full Mayo score of 2 or less, no subscore above 1). We used these factors to dev...
1 CitationsSource
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 20
#2Siddharth Singh (UCSD: University of California, San Diego)H-Index: 39
Last. WilliamJSandborn (UCSD: University of California, San Diego)H-Index: 142
view all 11 authors...
Background: Treatment targets for ulcerative colitis are evolving towards achievement of endoscopic improvement and remission in addition to symptom resolution. It remains to be accurately quantified what proportion of patients with symptom resolution have residual endoscopic activity that might warrant treatment modification. Aim: To quantify the prevalence of endoscopic improvement and remission amongst ulcerative colitis patients with various permutations of patient-reported outcomes. Methods...
Source
12345678910